UY31774A - Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos - Google Patents

Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos

Info

Publication number
UY31774A
UY31774A UY0001031774A UY31774A UY31774A UY 31774 A UY31774 A UY 31774A UY 0001031774 A UY0001031774 A UY 0001031774A UY 31774 A UY31774 A UY 31774A UY 31774 A UY31774 A UY 31774A
Authority
UY
Uruguay
Prior art keywords
ilcarboxamide
pyrimidin
substituted compounds
hsd1
inhibition
Prior art date
Application number
UY0001031774A
Other languages
English (en)
Inventor
Adrian Liam Gill
Leach Andrew
Packer Martin
James Stewart Scott
John Gibbin Swales
Paul Robert Owen Whittamore
Pernilla Soerne
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31774(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY31774A publication Critical patent/UY31774A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un compuesto de fórmula (I): y sales farmacéuticamente aceptables de este donde los grupos variables se definen en el interior; y también se describen su uso en la inhinbición de 11B(BETA)HSD1, procedimientos para prepararlos y composiciones farmacéuticas que los comprenden.
UY0001031774A 2008-04-22 2009-04-20 Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos UY31774A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4683608P 2008-04-22 2008-04-22
US14020108P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
UY31774A true UY31774A (es) 2009-12-14

Family

ID=40810517

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031774A UY31774A (es) 2008-04-22 2009-04-20 Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos

Country Status (24)

Country Link
US (1) US20090264401A1 (es)
EP (1) EP2271629A1 (es)
JP (1) JP2011518216A (es)
KR (1) KR20110002475A (es)
CN (1) CN102066335A (es)
AR (1) AR071387A1 (es)
AU (1) AU2009239794A1 (es)
BR (1) BRPI0910734A2 (es)
CA (1) CA2719936A1 (es)
CL (1) CL2009000967A1 (es)
CO (1) CO6321254A2 (es)
CR (1) CR11750A (es)
DO (1) DOP2010000323A (es)
EA (1) EA201001669A1 (es)
EC (1) ECSP10010561A (es)
IL (1) IL208405A0 (es)
MX (1) MX2010011591A (es)
NI (1) NI201000179A (es)
PE (1) PE20091810A1 (es)
SV (1) SV2010003713A (es)
TW (1) TW200948789A (es)
UY (1) UY31774A (es)
WO (1) WO2009130496A1 (es)
ZA (1) ZA201006993B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659659B (zh) 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
AU2008252185B2 (en) 2007-05-18 2012-02-16 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type I inhibitory activity
AU2009211215B2 (en) * 2008-02-04 2011-11-03 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
US20110092526A1 (en) * 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
RU2625309C2 (ru) 2011-04-22 2017-07-13 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
EP2735567B1 (en) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
US10093631B2 (en) 2014-02-14 2018-10-09 Acquist Llc Bifunctional compounds and use for reducing uric acid levels
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JP2018502896A (ja) 2015-01-22 2018-02-01 ピー．，ジュニア ワーレル，レイモンド 二機能性化合物および尿酸レベルを低下させるための使用
CN104628656A (zh) * 2015-02-11 2015-05-20 佛山市赛维斯医药科技有限公司 一类含嘧啶结构的对称环己烷羧酸酰胺类双靶点抑制剂及用途
CN104592131A (zh) * 2015-02-11 2015-05-06 佛山市赛维斯医药科技有限公司 含嘧啶结构的对称环己烷羧酸苄基酰胺类化合物及用途
CN104649980A (zh) * 2015-02-11 2015-05-27 佛山市赛维斯医药科技有限公司 含嘧啶结构的对称环己烷羧酸酰胺类sglt2/sglt1双靶点抑制剂、制备方法及用途
CN104649981A (zh) * 2015-02-11 2015-05-27 佛山市赛维斯医药科技有限公司 一种含嘧啶结构的对称环己烷羧酸苄基酰胺类双靶点抑制剂、制备方法及用途
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
TWI771303B (zh) 2016-06-30 2022-07-21 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途(一)
KR102445288B1 (ko) 2016-07-01 2022-09-19 쥐원 쎄라퓨틱스, 인크. N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성
TWI749024B (zh) 2016-07-06 2021-12-11 美商艾克奎斯特有限責任公司 化合物及其於降低尿酸位準之用途
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
TW202130623A (zh) * 2019-12-02 2021-08-16 美商富曼西公司 用於合成2-硫烷嘧啶的製程
TWI794994B (zh) * 2020-09-25 2023-03-01 大陸商上海美悅生物科技發展有限公司 嘧啶甲醯胺類化合物及其應用
CN115141147B (zh) * 2022-08-24 2023-09-12 绍兴上虞新银邦生化有限公司 一种n-甲基-3-取代甲基-4-吡唑甲酰胺衍生物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) * 1978-02-21 1981-03-27 Delalande Sa
FR2631028B1 (fr) * 1988-05-09 1990-07-13 Cird Adamantyl-2 isothiazoline-4 ones-3, leur procede de preparation et leur utilisation comme agents bactericides et fongicides
DE69304453T2 (de) * 1992-07-07 1997-02-06 Kyowa Hakko Kogyo Kk Pyridin-Derivate und diese enthaltende pharmazeutische Zubereitungen
AU7683500A (en) * 1999-10-12 2001-04-23 Takeda Chemical Industries Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
JP4178816B2 (ja) * 2001-03-15 2008-11-12 田辺三菱製薬株式会社 医薬組成物
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
US7459460B2 (en) * 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
JP2008519034A (ja) * 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
US20060235028A1 (en) * 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US20100022589A1 (en) * 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
US8329691B2 (en) * 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
JP2011502978A (ja) * 2007-11-06 2011-01-27 アストラゼネカ アクチボラグ ４−［４−（２−アダマンチルカルバモイル）−５−ｔｅｒｔ−ブチル−ピラゾル−１−イル］安息香酸−４６５
AU2009211215B2 (en) * 2008-02-04 2011-11-03 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
US20110092526A1 (en) * 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826

Also Published As

Publication number Publication date
BRPI0910734A2 (pt) 2015-09-29
TW200948789A (en) 2009-12-01
ZA201006993B (en) 2012-03-28
NI201000179A (es) 2011-12-15
WO2009130496A1 (en) 2009-10-29
AU2009239794A1 (en) 2009-10-29
EA201001669A1 (ru) 2011-06-30
MX2010011591A (es) 2010-11-09
CL2009000967A1 (es) 2010-06-11
SV2010003713A (es) 2011-02-17
CO6321254A2 (es) 2011-09-20
EP2271629A1 (en) 2011-01-12
PE20091810A1 (es) 2009-12-23
DOP2010000323A (es) 2010-12-15
CA2719936A1 (en) 2009-10-29
ECSP10010561A (es) 2010-11-30
JP2011518216A (ja) 2011-06-23
CN102066335A (zh) 2011-05-18
KR20110002475A (ko) 2011-01-07
US20090264401A1 (en) 2009-10-22
CR11750A (es) 2010-12-15
IL208405A0 (en) 2010-12-30
AR071387A1 (es) 2010-06-16

Similar Documents

Publication Publication Date Title
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
UY31524A1 (es) Nuevos compuestos 010
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
ECSP11011183A (es) Compuestos orgánicos
UY30759A1 (es) Compuestos quimicos
ECSP077271A (es) Derivados de pirimidina
ECSP077259A (es) Derivados de pirimidina
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181025